| 22.51 0.14 (0.63%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.52  |
1-year : | 28.93 |
| Resists | First : | 23.56 |
Second : | 24.77 |
| Pivot price | 22.85 |
|||
| Supports | First : | 21.62 | Second : | 17.98 |
| MAs | MA(5) : | 22.18 |
MA(20) : | 22.93 |
| MA(100) : | 23.7  |
MA(250) : | 19.89 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 21.5 |
D(3) : | 16.2 |
| RSI | RSI(14): 44.8 |
|||
| 52-week | High : | 27.71 | Low : | 9.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ELAN ] has closed above bottom band by 37.6%. Bollinger Bands are 2.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.76 - 22.86 | 22.86 - 22.94 |
| Low: | 21.97 - 22.07 | 22.07 - 22.17 |
| Close: | 22.35 - 22.51 | 22.51 - 22.66 |
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Sat, 02 May 2026
2,461,018 Shares in Elanco Animal Health Incorporated $ELAN Bought by Artemis Investment Management LLP - MarketBeat
Fri, 01 May 2026
Jennison Associates LLC Sells 1,347,898 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Wed, 29 Apr 2026
Analysts estimate Elanco Animal Health Incorporated (ELAN) to report a decline in earnings: What to look out for - MSN
Wed, 29 Apr 2026
Elanco Animal Health (ELAN) Leerink Global Healthcare Conference 2026 Summary - Quartr
Tue, 28 Apr 2026
Elanco Receives Emergency Authorizations for Negasunt Powder and Tanidil to Treat New World Screwworm in Livestock - iGrow News
Tue, 28 Apr 2026
/C O R R E C T I O N -- Elanco Animal Health/ - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 499 (M) |
| Shares Float | 493 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 109.3 (%) |
| Shares Short | 25,540 (K) |
| Shares Short P.Month | 15,070 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.17 |
| Profit Margin | -5 % |
| Operating Margin | 2.2 % |
| Return on Assets (ttm) | 1.2 % |
| Return on Equity (ttm) | -3.7 % |
| Qtrly Rev. Growth | 12.1 % |
| Gross Profit (p.s.) | 5.18 |
| Sales Per Share | 9.43 |
| EBITDA (p.s.) | 1.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 560 (M) |
| Levered Free Cash Flow | 560 (M) |
| PE Ratio | -47.9 |
| PEG Ratio | 3.9 |
| Price to Book value | 1.7 |
| Price to Sales | 2.38 |
| Price to Cash Flow | 20.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|